Search results
Results from the WOW.Com Content Network
High-dose chemotherapy using the CMVP combination was found to be able to be given safely to younger patients with high-risk breast cancer. The high-dose chemotherapy resulted in a significantly low relapse rate, and high-dose chemotherapy was associated with significantly longer disease-free and overall survival in this patient population.
Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved remission. [6]: 55–59
Preoperative PVE is a very well tolerated procedure with extremely low mortality rates (0.1 percent) and technical failure rates (0.4 percent). [3] Complication rates from the procedure are low as well (2–3 percent) and include portal vein thrombosis, liver infarction, necrosis, infection, pneumothorax, and other risks as listed above. [3]
Bristol-Myers Squibb Co (NYSE: BMY) has announced positive topline results from Phase 3 CheckMate 648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus BMY's Yervoy (ipilimumab ...
Once the chemotherapy is completed, the stored stem cells are infused back into the patient's body. This procedure helps to restore the bone marrow and support the recovery of blood cells. ASCT has allowed for the administration of HDC, with improvements in supportive care reducing associated morbidity and mortality. [1] [2]
Metronomic therapy is also cost-effective as a lower dose is used compared to conventional chemotherapy. [2] The use of metronomic therapy has been extensively investigated and can be advantageous in selected group of patients. [3] Yet, more clinical trials are necessary to generalize the method. [4]
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
With a minimum follow-up of 21.0 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression, or death by 37% across randomized patients when administer